Table 1.
Response Chart
| 6‐mo PFS Rate, % | PFS Time, mo | Best Response: RECIST, No. (%) | Best Response: Choi, No. (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarcoma Subtype | Source | Drug | No. | RECIST | Choi | RECIST | Choi | CR/PR | SD | PD | CR/PR | SD | PD |
| SFT | Stacchiotti 201210 | Sunitinib | 31 | 45 | ‐ | ‐ | 7 | PR: 2 (6.5) | 17 (54) | 12 (39.5) | PR: 14 (48) | 5 (17) | 10 (35) |
| Park 201111 | Temozolomide, bevacizumab | 14 | 93 | 79 | 10.8 | 9.67 | PR: 2 (14) | 12 (86) | 0 | PR: 11 (79) | 2 (14) | 1 (7) | |
| Park 201312 | Conventional chemotherapy | 25 | ‐ | ‐ | 4.6 | ‐ | 0 | 21 (84) | 4 (16) | ‐ | ‐ | ‐ | |
| Schuetze 20162 | Dasatinib | 25 | ‐ | 30 | ‐ | 2 | 0 | ‐ | ‐ | PR: 5 (20) | ‐ | ‐ | |
| Chordoma | Bompas 201523 | Sorafenib | 27 | 85 | ‐ | NR | ‐ | PR: 1 (8) | 12 (84) | 1 (8) | PR: 7 (54) | 5 (38) | 1 (8) |
| Stacchiotti 201321 | Lapatinib | 18 | ‐ | ‐ | 8 | 6 | 0 | 15 (83) | 3 (17) | PR: 6 (33) | 7 (39) | 5 (28) | |
| Stacchiotti 201220 | Imatinib | 56 | 64 (CBR) | ‐ | 9.2 | ‐ | PR: 1 (2) | 35 (70) | 14 (28) | ‐ | ‐ | ‐ | |
| Hindi 201522 | Imatinib | 50 | 65 | ‐ | 9.9 | ‐ | 0 | 34 (74) | 12 (26) | ‐ | ‐ | ‐ | |
| Schuetze 20162 | Dasatinib | 32 | ‐ | 54 | N/A | 6.3 | 0 | ‐ | ‐ | 6 (19) | ‐ | ‐ | |
| ASPS | Kumar 201313 | Cediranib | 43 | 84 | ‐ | ‐ | ‐ | PR: 15 (35) | 26 (50) | 2 (15) | ‐ | ‐ | ‐ |
| Wagner 201215 | Tivantinib | 27 | ‐ | ‐ | 5.5 | ‐ | 0 | 21 (78)* | 5 (19) | ‐ | ‐ | ‐ | |
| Stacchiotti 201214 | Sunitinib | 9 | 88 | ‐ | 17 | ‐ | 5 (55) | 3 (33) | 1 (11) | ‐ | ‐ | ‐ | |
| Schuetze 20162 | Dasatinib | 12 | ‐ | 62 | 11 | 0 | ‐ | ‐ | PR: 1 (8) | ‐ | ‐ | ||
| Chondrosarcoma | Italiano 201316 | GDC‐0449 (hedgehog) | 39 | 25.6 (CBR) | ‐ | 3.5 | ‐ | 0 | 10 (26) | 29 (74) | ‐ | ‐ | ‐ |
| Fox 201218 | Gemcitabine plus docetaxel | 25 | ‐ | ‐ | ‐ | ‐ | 2 (8) | 14 (56) | 9 (36) | ‐ | ‐ | ‐ | |
| Grignani 201017 | Imatinib | 26 | 31 4‐mo PFS | ‐ | 3 | ‐ | 0 | 8 (31) | 18 (69) | ‐ | ‐ | ‐ | |
| Italiano 201419 | Assortment of drug combinations | 180 | 44 | ‐ | 4.7 | ‐ | CR: 2 (1) PR: 22 (14) | 67 (41) | 72 (45) | ‐ | ‐ | ‐ | |
| Schuetze 20162 | Dasatinib | 33 | ‐ | 47 | ‐ | 5.5 | 0 | ‐ | ‐ | PR: 5 (15) | ‐ | ‐ | |
| Epithelioid sarcoma | Pink 201425 | Gemcitabine plus docetaxel | 12 | ‐ | ‐ | 8 | ‐ | CR: 1 (8) PR: 6 (50) | 3 (25) | 2 (17) | ‐ | ‐ | ‐ |
| Jones 201224 | Conventional chemotherapy | 20 | 53 | ‐ | 6.7 | PR: 3 (15) | 12 (60) | 5 (25) | ‐ | ‐ | ‐ | ||
| Schuetze 20162 | Dasatinib | 7 | ‐ | 57 | ‐ | 7.9 | 0 | ‐ | ‐ | PR: 2 (29) | ‐ | ‐ | |
Abbreviations: ASPS, alveolar soft part sarcoma; CBR, Clinical Benefit Rate (CR+PR+SD); CR, complete response; N/A, not available; NR, not reported; PD, progressive disease; PFS, progression‐free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SFT, solitary fibrous tumor. * For Wagner et al, 1 patient was inevaulable.